Evommune vs Relay Therapeutics
Relay Therapeutics is the larger business, with $15.4m of revenue in fiscal 2025 against $13.0m for Evommune (1.2 times as much). Evommune grew faster (85.7% against 53.4%). Evommune kept more of each dollar of sales as profit: a net margin of -529.8% against -1800.6%. Evommune carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | EvommuneEVMN, 2025 | Relay TherapeuticsRLAY, 2025 |
|---|---|---|
| Revenue | $13.0m | $15.4m |
| Revenue growth | 85.7% | 53.4% |
| Net income | −$68.9m | −$276m |
| Operating margin | -623.6% | -1971.6% |
| Net margin | -529.8% | -1800.6% |
| Return on equity | — | -41.1% |
| Free cash flow | −$76.7m | −$236m |
| Cash | $44.1m | $84.0m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 48 | 192 |
| Market value | $215m | $3.84bn |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 7 buys, 9 sales | 0 buys, 40 sales |